key: cord-0881278-0iyamx7v
authors: Martín-Bravo, Celia; Quirós, Raúl; Blancas, Isabel; Villatoro-Roldán, Rosa; Robles, Marta; Alcaide, Julia; Navarro, Víctor; Pérez, Diego; Zarcos, Irene; Rivas-Ruiz, Francisco; Pérez-Ruiz, Elisabeth; Quero, Cristina
title: Incidence of COVID-19 in outpatients with cancer receiving active treatment in the context of a pandemic: An Andalusian cohort study
date: 2021-01-29
journal: Semin Oncol
DOI: 10.1053/j.seminoncol.2021.01.002
sha: 7832894b74e8ae2d56375f6b63acd77337566df1
doc_id: 881278
cord_uid: 0iyamx7v

Background: Leading scientific societies have recommended delaying and/or suspending active cancer treatment during the COVID-19 pandemic. Nevertheless, data on this novel infection in patients with a diagnosis of cancer receiving active treatment are scarce and it is unknown if these recommendations could have repercussions on future progress of the disease. The main objective of this study is to learn the COVID-19 incidence rate in outpatients with cancer receiving active treatment. Methods: This work is a retrospective cohort study that included all patients with a diagnosis of cancer who received active cancer treatment in two Andalusian hospitals between February 26 and May 13, 2020. Variables regarding the patient, tumor, and development of COVID-19 were collected. A descriptive analysis was performed and the cumulative incidence of COVID-19 in these patients was evaluated. Results: A total of 673 patients were included. The median age was 62 years. There was a low rate of comorbidity and 12.1% had an ECOG >2. Breast cancer was the most common cancer (41%), followed by colorectal and lung cancer. Stage IV cancer was reported in 52.7% of patients. The most common treatment was chemotherapy (53.9%). Treatment was delayed or suspended in 6% of patients. Only three patients developed COVID-19. The cumulative incidence was 0.44% and one person died due to infection. Conclusions: In the present retrospective cohort study, we found a low incidence of COVID-19 infection in patients with cancer receiving active treatment in an outpatient setting. The sociodemographic factors of Andalusia may explain why these results differ from those presented by other colleagues in Spain, but raise questions about whether universal recommendations may put the benefits of antineoplastic therapy at risk.

The pandemic caused by the novel coronavirus SARS-CoV-2 2 [1] is giving rise to unprecedented social and medical measures, 3 especially in at-risk groups such as patients with cancer. These pa-4 tients, who are more susceptible to infection due to their illness 5 and the treatments they receive, are considered to be at high risk 6 of contracting and dying from COVID-19 [2] . Leading scientific societies have recommended that active treat- 8 ment be delayed or suspended in these patients during the pan- 9 demic [3 , 4] . However, these recommendations are based on small, 10 retrospective studies carried out in China, in which greater morbid-11 ity and mortality was described in cancer patients who developed 12 SARS-CoV-2 infection. 13 On the one hand, during a pandemic, the potential for benefit- 14 ing from chemotherapy would remain unchanged, but the risk of 15 harm would be increased to a degree that cannot really be quan-16 tified. A study by Liang et Both studies concluded that patients with cancer who were receiv- 140 ing treatment were at greater risk of adverse events due to COVID-141 19 than patients with cancer who were not receiving treatment. 142 Mortality, which was only reported in the study by Zhang et al [8] , 143 was 28.6% among patients with cancer, though it was not specified 144 how many of these patients were receiving active treatment. 145 This pandemic has severely affected the "old continent," and 146 as such has allowed for the reporting of more solid-albeit 147 heterogeneous-data on patients with cancer. Lee et al [7] , prospec-148 tively analyzed mortality due to COVID-19 in 800 patients diag-149 nosed with cancer that were in active treatment. This study de-150 fined patients in active treatment as those who had received any 151 cancer treatment (including surgery, chemotherapy, radiotherapy, 152 hormone therapy, targeted therapy, or immunotherapy) in the pre-153 vious 12 months. This definition encompasses outpatients, as in 154 our study. They examined the baseline characteristics of these pa-155 tients and found that 56% were male, a figure similar to the Chi-156 nese studies but different to ours. The patients primarily had can-157 cer of the digestive organs (19%), breast cancer (13%), and lung can-158 cer (11%), with metastatic disease found in 43%. Twenty-one per-159 cent had no comorbidities and just 33% had received chemother-160 apy in the 4 weeks prior to COVID-19 diagnosis (which represents 161 a total of 264 patients receiving outpatient treatment). They did 162 not find greater mortality among patients who had received can-163 cer treatment versus those who had not, a finding that differed 164 from previous publications. They also did not find differences in 165 mortality adjusted for the type of cancer treatment received and 166 concluded that mortality seemed to depend more on advanced age 167 and the presence of comorbidities unrelated to the cancer. 168 Rogado et al [6] published the first Spanish study on patients 169 with cancer and COVID-19 in which they retrospectively analyzed 170 1,069 patients hospitalized in the medical oncology department. 171 They reported an incidence of COVID-19 of 4.2% and a mortality 172 rate among these patients of 42.2%. Those who died tended to be 173 older and whether or not they were receiving treatment or the 174 type of treatment did not appear to play a role. [6] This group of 175 patients with cancer and COVID-19 had a median age of 71 years 176 (somewhat older than those in our study), 57.8% had stage IV dis-177 ease, 37.8% had lung cancer, and 28.9% were not receiving active 178 treatment [6] . 179 Recently, Yarza et al [10] published another Spanish study-180 conducted in the Community of Madrid, and like the study by Ro-181 gado et al [6] -which prospectively analyzed 287 cases of patients 182 with cancer seen in consultation for any reason, related or not to 183 SARS-CoV-2 infection, in the oncological emergency units for pa-184 tients receiving treatment. All were screened for SARS-CoV-2 ei-185 ther via PCR, radiography, or clinical analysis. Ninety required ad-186 mission in order to administer in-hospital treatment for COVID-19. 187 Of those 90, the first 63 patients seen in consultation were stud-188 ied: 52 (83%) had been diagnosed with COVID-19 via PCR (inci-189 dence of 18.11% out of the original 287); the remaining 11 (17%) 190 were diagnosed due to findings that were highly clinically and ra-191 diologically suspicious. The 63 hospitalized patients had a mean 192 age of 66 years, 46% were women, 82% were receiving treatment 193 for metastatic disease (only 4% were not in active treatment and 194 50% of the cancer treatments were chemotherapy), and 27% had 195 lung cancer. 196 Unlike our study, this group [6] analyzed the incidence of SARS-197 CoV-2 infection among 63 patients with cancer who had COVID-19 198 seen in consultation for any reason in a hospital where they were 199 screened via PCR (many of them were asymptomatic). This is likely 200 one reason why the incidence found in studies differs consider-201 ably, given that in our study, in addition to including all outpa-202 tients receiving active treatment, we only performed PCR tests on 203 patients who presented with symptoms or who had radiological 204 findings characteristic of SARS-CoV-2 infection; PCR tests were not 205 performed on asymptomatic patients. In the study by Yarza et al 206 [10] , mortality was 25.4%, compared to 33% (1/3) in our study and 207 much lower than what was reported in another healthcare district 208 in the same autonomous community (Madrid) by Rogado et al [6] . 209 It should be noted that the incidence of COVID-19 in the Commu-210 nity of Madrid has been much higher than in Andalusia [10] . 211 The mortality in patients with cancer has been reported as 212 higher than in patients without cancer with a range between 11.4% 213 and 42.2% [6] [7] [8] [9] [10] , depending on the cohort analyzed. Advanced age 214 seems to be an independent factor related to mortality, though 215 non oncological comorbidity is an aspect to take into account. 216 When comparing non oncological comorbidities among published 217 reports ( The authors declare that they have no known competing finan-258 cial interests or personal relationships that could have appeared 259 to influence the work reported in this paper. The authors have no To our patients and their family members, whose cooperation 273 is fundamental in the fight against cancer. To our colleagues in 274 healthcare on the front lines of the battle against COVID-19, whose 275 work and humanity know no limits and who deserve our respect, 276 admiration, and gratitude. 277 We would like to thank the Research Unit of the Costa del 278 Sol Healthcare Agency for their support in the translation of the 279 manuscript. 280 

Clinical characteristics of Coronavirus disease Q6 282 2019 in China

Cancer statistics in China

A practical approach to 286 the management of cancer patients during the novel Coronavirus disease 287 2019 (COVID-19) Pandemic: an international collaborative group

Cancer guidelines during the COVID-19 pandemic

Cancer patients in SARS-CoV-2 infection: a 292 nationwide analysis in China

Covid-19 transmission, outcome and asso-294 ciated risk factors in cancer patients at the first month of the pandemic in a 295 Spanish hospital in Madrid

COVID-19 mortality in patients with cancer 297 on chemotherapy or other anticancer treatments: a prospective cohort study

Clinical characteristics of COVID-19-infected cancer 300 patients: a retrospective case study in three hospitals within Wuhan

Patients with cancer appear more vulnerable to 303 SARS-CoV-2: a multicenter study during the COVID-19 outbreak

SARS-CoV-2 infection in cancer patients 306 undergoing active treatment: analysis of clinical features and predictive factors 307 for severe respiratory failure and death